ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2625

Associations Between Achieved Hemoglobin and Cardiovascular Outcomes in the Pooled Phase 3 Roxadustat Studies of Non-Dialysis-Dependent Patients with Anemia of CKD

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Fishbane, Steven, Northwell Health, Great Neck, New York, United States
  • Provenzano, Robert, Wayne State University, Detroit, Michigan, United States
  • Pergola, Pablo E., Renal Associates, PA, San Antonio, Texas, United States
  • Szczech, Lynda, FibroGen Inc, San Francisco, California, United States
  • Leong, Robert, FibroGen Inc, San Francisco, California, United States
  • Saikali, Khalil Georges, FibroGen Inc, San Francisco, California, United States
  • Zhong, Ming, FibroGen Inc, San Francisco, California, United States
  • Lee, Tyson T., FibroGen Inc, San Francisco, California, United States
  • Little, Dustin J., AstraZeneca, Gaithersburg, Maryland, United States
  • Frison, Lars, AstraZeneca, Molndal, Sweden
  • Houghton, John, AstraZeneca, Gaithersburg, Maryland, United States
  • Yu, Kin-Hung Peony, FibroGen Inc, San Francisco, California, United States
Background

Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, promotes erythropoiesis and increases bioavailability of iron. In phase 3 studies, roxadustat-treated patients achieved and maintained hemoglobin (Hb) values of 11±1 g/dL. We examined the associations between achieved Hb levels and cardiovascular outcomes in non-dialysis-dependent (NDD) patients with anemia of chronic kidney disease (CKD).

Methods

We analyzed pooled data from 3 pivotal, phase 3 studies of patients with anemia of NDD-CKD who received roxadustat. Incidence rates of adjudicated MACE (all-cause mortality, MI, and stroke) and MACE+ (MACE plus heart failure and unstable angina requiring hospitalization) were evaluated based on 1) Hb level immediately before the event and 2) maximum Hb level in the first 12 treatment weeks.

Results

Overall, 2391 patients were randomized to roxadustat. The mean (SD) baseline Hb of 9.1 (0.74) g/dL increased to 10.95 (0.76) g/dL over weeks 28-52. The MACE and MACE+ rates were highest when Hb was < 8 g/dl decreasing as Hb increased to 11-12 g/dL and ≥12 g/dL (Table).

Conclusion

In the NDD-CKD population, roxadustat corrected anemia and maintained Hb to 11±1 g/dL during weeks 28-52. MACE and MACE+ incidence rates were lowest when achieved Hb levels were ≥11g/dL.

Funding

  • Commercial Support